GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CTT Pharmaceutical Holdings Inc (OTCPK:CTTH) » Definitions » Tax Expense

CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Tax Expense : $0.00 Mil (TTM As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is CTT Pharmaceutical Holdings Tax Expense?

CTT Pharmaceutical Holdings's tax expense for the months ended in Jun. 2018 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2018 was $0.00 Mil.


CTT Pharmaceutical Holdings Tax Expense Historical Data

The historical data trend for CTT Pharmaceutical Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTT Pharmaceutical Holdings Tax Expense Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CTT Pharmaceutical Holdings Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Mar17 Jun17 Mar18 Jun18
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CTT Pharmaceutical Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTT Pharmaceutical Holdings  (OTCPK:CTTH) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


CTT Pharmaceutical Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of CTT Pharmaceutical Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
1100 – 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6
CTT Pharmaceutical Holdings Inc is a development stage company specializing in drug delivery systems technology within the pharmaceutical industry. It focuses on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The thin wafers are infused with both natural and synthetic cannabis extracts to deliver treatment as an alternative to smoking and ingestion. Its products include Medwafe, Cannawafe, Vetwafe, and others.
Executives
Albert C Zapanta director PO BOX 2020, SPRINGDALE AR 72765
William Thomson director 390 BAY ST, SUITE 1102, TORONTO ONTARIO A6 M5H 2Y2